Postoperative fibrosis is a frequent consequence of surgical procedures in the epidural space. Compression or tethering of the nerve root often causes recurrent radicular pain and physical impairment.1,2 An epidural scar occurs after lumbar discecto~y by replacement of normal epidural fat with fibrotic tissue. Spinal nerve roots and dorsal root ganglions are particularly sensitive to mechanical deformation caused by epidural Ross, et ar reported that patients '... :_-----, --. -dural scar were 3.2 times more likely to experience recurrent radicular pain than patients with less :.-scarring. When Hurme et al5 examined 40 patients 5 years after primary surgery for herniated lumbar disc, 18 were found to have an increased amount of scar tissue, which correlated with poor results. Thus, extensive epidural fibrosis occurring after lumbar surgery contributes to failed back surgery syndrome (FBSS), characterized by recurrent radicular or lower back and leg pain. 3, 6, 7 Acquisition of meticulous hemostasis is an effective surgical technique for reducing epidural fibrosis.8 In addition to good surgical technique,9 many materials have been implanted on the dura in an effort to prevent or reduce scar formation after surgery in the epidural space. [10] [11] [12] [13] [14] [15] Results from preclinical studies have demonstrated reduction of epidural fibrosis with a variety of implanted devices. [16] [17] [18] One such formulation, Adcon-L (Gliatech, Cleveland, OH), has received FDA approval for scar reduction after lumbar surgery. 19 Widespread use of Adcon-L was limited by reports of late-onset headaches and associated leakage of CSF from dural injuries potentially related to delayed healing and foreign body reaction.2o-24
Oxiplex/SP Gel is composed of polyethylene oxide (PEO) and sodium carboxymethylcellulose (CMC). Calcium chloride is added to induce ionic cross-linking. Both CMC and PEa are known to reduce adhesions and fibrotic scarring that form after surgery . 25, 26 Because CMC is rapidly resorbed, calcium chloride is added to the formulation to create stronger interaction between the components, thereby prolonging residence in the body.26,27 Studies of rabbit laminotomies have demonstrated by gross morphology and histology that Oxiplex/SP Gel is cleared from the epidural space within 30 days and effectively reduces epidural scar.29 Furthermore, Oxiplex/SP Gel did not affect dural repair and was not associated with chronic inflammation or foreign body response. This article reports results from a pilot clinical trial of Oxiplex/SP Gel performed in accordance with the FDA, which demonstrated reduction of postoperative pain and radiculopathy in patients after discectomy via laminectomy or laminotomy. assignment: to receive Oxiplex/SP Gel or not to receive any additional adhesion prevention treatment (control condition). Any hemostatic agents used during surgery were removed before closure of the surgical site. All the patients underwent closure in the surgeon's routine fashion. The test patients received sufficient Oxiplex/SP Gel to coat the nerve roots and fill the operative site (approximately 3 mL).
Inclusion Criteria. The patients were adults scheduled to undergo their first surgery for removal of a unilateral, herniated, lumbar, intervertebral disc associated with radiculopathy. Specific inclusion criteria required signs and symptoms of lumbar or lumbosacral radiculopathy affecting one predominant nerve root level, radiologic evidence of nerve root compression, and/or confirmed existence of an extruded or sequestered disc fragment at L4-LS or LS-Sl compatible with clinical signs and symptoms. Preoperative laboratory test results needed to be within normal limits or deemed not to be of clinical significance by the investigator.
The patients included in the study underwent at least 2 weeks of nonoperative treatment without resolution of pain, which the surgeon could waive if the patient was experiencing intractable pain or progressive loss of neurologic function. During the 2-week nonoperative period, the physician treated the patient as necessary with physical therapy, narcotics, or any other nondisqualifying treatments that would alleviate the patient's discomfort. No patient had epidural steroid treatment withheld to qualify for the study.
. Materials and Methods
Study Design. This randomized, single-blind, multicenter, pilot clinical trial study evaluated the safety of Oxiplex/SP Gel in reducing postoperative epidural fibrosis and related symptoms after surgery for herniated lumbar disc at L4-L5 or L5-S1. Patients underwent presurgical eligibility evaluations, including examination by a neurosurgeon or orthopedic spine surgeon, and magnetic resonance imaging (MRI) of the spine.
A self-assessment questionnaire (Lumbar Spine Outcomes Questionnaire [LSOQ]) related to patients' pain, symptoms, and activities of daily living was completed before surgery and at scheduled postoperative intervals (30 days, 90 days, 6 months).30.31 A computer-generated paradigm randomized patients to a treatment (Oxiplex/SP Gel) or control (no Oxiplex/SP Gel) group with balanced assignment across the study and per center. Randomization occurred immediately before wound closure. The study patients were not informed as to their group assignment until after data analysis. Both patient groups underwent follow-up MRI evaluations 90 days after surgery, with and without gadolinium contrast. All the MRIs were reviewed by two masked neuroradiologists. At 30 and 90 days after surgery, all the patients were assessed by physical examination, lower extremity neurologic function, wound inspection, self-assessment LSOQ, and laboratory tests including CBC, chemistry panel, and urinalysis.
Exclusion Criteria. Patients were excluded if they had undergone previous spinal surgery, had been treated with epidural steroids within 4 weeks or oral steroids within 10 days of the proposed surgery, and/or had received aspirin or other nonsteroidal antiinflammatory drugs within 7 days of the proposed surgery. Patients who had received myelograms or lumbar punctures within 24 hours before surgery also were excluded. Other exclusion criteria specified any concurrent disease that, in the surgeon's opinion, could influence the outcome of the proposed surgery, any postoperative involvement in a current or anticipated worker's compensation claim, or any involvement in a current or anticipated personal injury litigation. Patients were excluded intraoperatively for dural entry, discovery of intraspinal tumor, the need to involve more than one level, exploration of the contralateral side, placement of an epidural fat pad. or retention of a hemostat.
Maintaining the Study Blinding. The following procedures were used to maintain blinding for all ratings and assessments. The investigator, site study coordinator, and other applicable site personnel agreed not to discuss the treatment assignments during the course of the study, or to provide any documents to the patient that may have revealed the assignment (e.g., an operative report). The patients completed the self-assessment questionnaires before meeting with the physician or study coordinator.
Randomization. Randomization was assigned when the patient's surgical procedure was completed to the point at which hemostasis was assured and the surgeon was ready to close the operative site. At that time, the sponsor was called for patient Leg Pain Severity Measure. Severity of leg pain was assessed on a 6-point adjective rating scale indicating the severity of leg or buttock pain: 1 (hurts the most), 2 (hurts the least), 3 (average pain), 4 (pain at the end of an active day), 5 (pain on awakening), and 6 (pain at the moment of response to the questionnaire). The responses were converted to numerical values ranging from 0 (no pain) to 5 (excruciating pain). Six scores were thus obtained for each patient at each evaluation. These scores were combined and rescaled to yield composite leg pain severity scores in the range of 0 to 100. t test or the Wilcoxon matched-pairs signed-rank test. For each of the five composite measures, analyses of variance (ANOV A) were used to evaluate changes from baseline and to compare the two groups (Oxiplex/SP Gel and control groups). Changes in lower extremity weakness were evaluated using Fisher's exact test.
For each patient, an absolute and a relative change were computed. The absolute change scores were computed from the differences between the values reported at the 30-day, 90-day, and 6-month follow-up assessments and the corresponding baseline values. Relative change scores, expressed as percentages, were computed by subtracting the posttreatment value from the baseline value, then dividing by the baseline value. For all analyses, P values less than 0.05 were considered significant.
Physical Symptoms and Radiculopathy
Score. On a 4-point scale (never, occasionally, frequently, and always), patients indicated how often they had experienced the following symptoms during the preceding 7 days: numbness or tingling in the lower extremities, weakness in the lower extremities, bowel or bladder dysfunction, and trouble falling asleep or being awakened from sleep because of pain. The responses were converted to numerical values ranging from a (never) to 3 (always), then combined and rescaled to yield physical symptoms scores ranging from a to 100. A radiculopathy score was obtained by summing the leg pain severity scores and the symptoms scores, then dividing by 1.
MRI Evaluation.
Although evaluation of MRI images generally has not predicted the clinical response to surgery, it has provided a useful safety assessment of postsurgical repair ,33-38 Magnetic resonance imaging was performed at 90 days (12-14 weeks) with and without gadolinium contrast. Epidural abnormality was defined as a low T1 signal of epidural material. Enhanced and nonenhanced quadrant scores were recorded on the MRI case report form (CRF). The amount of abnormality was graded on a scale of 0 to 6 for each quadrant: 0 (none), 1 (0-5%),2 (6-25%), 3 (26-50%),4 (51-75%), 5 (76-95%), and 6 (96-1000;0) of epidural space.
Statistical analysis of MRI quadrants for each of the five 2-mm slices was performed using a categorical variable analysis. The reliability of MRI scores was assessed using weighted kappa coefficients for ordinal data. Functional Disability and Activity-Related Pain Scores. On a 4-point scale (all, most, some, and none), the patients indicated how many of their daily activities they could perform, the number of days they could not perform work-related activities, the number of hours they spent during the day resting, and the activities on a provided list that exacerbated their pain. 32 The eight scores were combined and rescaled to yield composite functional disability scores in the range of 0 to 10. The patients indicated, from a list of 12 activities of daily living, whether each activity increased, decreased, or left unchanged their pain. Their responses were converted to numerical values and rescaled, as previously described. 32 .
Results
All the patients (23 in the Oxiplex/SP Gel group and 12 in the control group) tolerated the surgical procedures well and had good postoperative recoyery Table 1 ). There were no device-related adverse events. As determined by the principal investigator, the adverse events that did occur were consistent with typical postoperative recovery. There were no clinically significant changes in laboratory values. The MRI analysis, including observations of enhancing and nonenhancing abnormalities, did not show significantly different results between the con- greater for most categories at 6 months in the Oxiplex/SP Gel-treated group than in the control group (Figure 1 ).
. Discussion
Focal limitation of epidural scar formation, while maintaining healing of the surgical site, necessitates understanding the natural history of epidural fibrosis!3,39,4o Fibrosis can form between spinal dura mater and interposing structures as a result of hematoma or residual necrotic tissues, including fat:l Inflammatory reaction to foreign substances also enhances fibrogenesis:2 It is reported that fewer than one third of the patients who undergo reoperation after lumbar disc surgery show persistent improvement of their symptoms. The chance of long-term surgical success after reoperation is considerably diminished in cases wherein epidural fibrosis is prevalent.43-45 Repeated surgery for epidural fibrosis not only is less successful, but also involves prolonged operating time and increased risks for adhesive arachnoiditis and dural tears resulting from scarification by fibrosis at the surgical site.14,43,44,46,47 Pain scales are a common method for assessing patient outcome after back surgery. At least 22 scales exist in the literature.30,48 However, the presence of pain alone is a narrow definition of outcome that correlates poorly with physical function:9 Recording disability in daily tasks may reduce subjective differences in evaluation ofsymptoms and provides a measure with less potential bias. Waddell and Main50 stated that in evaluating clinical outcome of surgery for low back pain, three components require consideration: pain, physical impairment, and disability. As a result, many contemporary studies use multiple questionnaires to assess treatment outcomes.30 BenDebba et aZ31,32 developed a comprehensive, diseasespecific questionnaire for assessing reports of low back pain and evaluating the outcomes of treatments for these reports. This instrument, the Lumbar Spine Outcome Questionnaire (LSOQ), was used to evaluate the response of 2539 patients undergoing treatment for low back pain. The questionnaire was shown to have high test-retest reliability, good content and construct validity, and responsiveness to change after treatment. It was trol and treated patients. The median scores, determined from all four quadrants of five slices for the control patients (n = 10) and the treated patients (n = 23), were, 1.755 and 1.550 for the enhanced scores and 0.125 and 0.100 for the nonenhanced scores, respectively. There were no significant differences in MRI values between the two evaluators (kappa coefficient, 0.654). The results from the Lumbar Spine Outcomes Questionnaire (LSOQ) 30 days, 90 days, and 6 months after surgery for all the patients are shown in Table 2 .
In this small pilot study, there were no statistically significant differences between the treated patients and the control patients on the five composite scores and the single:-item score derived from the LSOQ questionnaire. Overall, the symptoms were reduced in the Oxiplex/SP Gel-treat~d patients in all the time points. Weakness in the lower extremity was reduced in the Oxiplex/SP Geltreated patients, as compared with the control patients, at the 30-day time point (P = 0.052). The radiculopathy score also was reduced in the Oxiplex/SP Gel-treated patients at the 30-day time point (P = 0.091). In general, the patients who received Oxiplex/SP Gel had lower LSOQ scores than the control patients 30 days after surgery (Table 2 ). These differences in scores at 30 days were attenuated or not present at 90 days and 6 months.
Analysis of preoperative scores showed a subgroup of patients (11 patients treated with Oxiplex/SP Gel and 7 control patients) who had substantial leg pain (score, 40) and weakness in the lower extremity (score, >2) at baseline ( Table 3) . Evaluation of LSOQ scores in this subgroup demonstrated differences in treatment response in all categories 30 days, 90 days, and 6 months after surgery. Reduction in leg pain scores (P = 0.038), symptoms (P = 0.015), weakness in the lower extremity (P = 0.023), and radiculopathy score (P = 0.017) at 30 days for the Oxiplex/SP Gel-treated patients all were statistically lower than for the control patients. All change from baseline scores at 30 days, 90 days, and 6 months showed reductions in the Oxiplex/SP Geltreated patients, as compared with the control patients. The relative change from baseline in LSOQ scores was . Patients with a herniated disc, significant pain, and lower extremity weakness reported clinical benefit with the use of Oxiplex/SP Gel . The safety profiles of the Oxiplex/SP Gel-treated patients and the surgical controls were the same after lumbar discectomv.
reported to be acceptable to patients and easy to administer. The LSOQ was used in this study as an instrument designed specifically to measure clinical outcomes after lumbar discectomy for herniated discs in patients with pain and radiculopathy. Interpretation of clinical data from FDA-monitored safety studies is limited beyond general safety consideration because the number of patients was small. Unlike pivotal studies, which often contain more than 250 patients, safety studies, which precede pivotal studies in the United States, typically have only 20 to 30 patient exposures to the device. In this study, the number of patients treated with Oxiplex/SP Gel was 23. The utility of the clinicaY trial data is dependent on the comparability of data at baseline. In this study, interpretation of the outcomes mea~ure was limited by differences in baseline values. The difference in baseline values for the leg pain category was particularly problematic. When the relatively low-scoring patients were removed from consideration, the baseline values for leg pain became similar (64.5 vs 66.3, Table 3 ), and a difference in treatment response became apparent (leg pain, 67% vs50%, relative change). When this group of patients was analyzed, a clear separation in clinical outcome measures between the Oxiplex/SP Gel-treated patients and the control patients was evident (Table 3) , which continued through the 6-month study interval (Figure 1 ). Although subgroup analysis is notoriously misguided, in this case identification of this subgroup (patients with leg pain scores, ~40; lower extremity weakness, >2) assisted in the design of the pivotal study.
In conclusion, patients treated with Oxiplex/SP Gel had safety profiles similar to those of the surgery-only control patients. In the patients with significant leg pain and lower extremity weakness at baseline, the patients who received Oxiplex/SP Gel had a general improvement in OIltcome. a~ com oared with the control oatients. Con- 
